Additionally, other PD-1 or PD-L1 inhibitors were also available for the patients with advanced GC when they failed the administration of apatinib plus PD-1 blockades, bringing the patients with OS benefits consecutively. This evidence concerns the gene PDCD1 and gastric cancer.